Mineralys Therapeutics, Inc. (MLYS)
After hours:
- GuruFocus.com
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares
On June 14, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a sale of 72,797 shares of the company, according to the SEC Filing.
- GlobeNewswire
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that Alexander M. Gold, M.D. has been appointed to the Company's Board of Directors (the Board), effective June 13, 2024. “We are delighte
- GuruFocus.com
Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)
On June 11, 2024, Adam Levy, the Chief Financial Officer and Secretary of Mineralys Therapeutics Inc (NASDAQ:MLYS), sold 96,815 shares of the company.
